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OBJECTIVES: Chronic obstructive pulmonary disease(COPD) is a highly prevalent dis-
ease and the sixth cause of death in Korea. This study examined the national epide-
miology and economic impact of COPD in Korea. METHODS: This study used the
societal cost of illness framework, consisting of epidemiology of COPD, directmedical
costs,directnon-medical costs, and indirect costs.National-levelhealthsurvey results
and insurance claim databases were used to analyze annual healthcare utilization,
hospitalization costs and outpatient costs of the total Korean population (48 million
people). Using a data mining technique, we identified medical claims with interna-
tional classification of disease 10 codes for COPD and estimated the costs by amacro-
costingmethod.RESULTS: The prevalence rate of COPDbased on theGlobal Initiative
for chronic obstructive lung disease(GOLD) criteria was estimated at 13.1% and its
mortality rate was 14.9 persons per 1,000 population in 2008. According to the classi-
fication of the GOLD, for the population over 45 years, the stage 1 group accounted for
the largest proportion(55.2%), followed by the stage 2(37.2%), stage 3(6.4%), and stage
4(1.2%). The total societal cost of COPD in 2009 was estimated at $266.4 million for
700,812 patients. The directmedical cost for COPDwas $148.7million, which includes
hospitalization cost of $72.8 million and outpatient cost of $75.9 million. The direct
non-medical cost, involving transportation cost and caregiver cost, was estimated at
$20.4 million. Indirect costs associated with morbidity and mortality of COPD were
$97.3 million. CONCLUSIONS: The study showed that the COPD had a great effect on
healthcare costs, particularly thedirectmedical cost. Therefore, appropriate interven-
tion that result inpatientswithCOPDspending less time in thehospital are likely to be
cost effective and long-term regular management is also necessary to lower the eco-
nomic burden of COPD in Korea.
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OBJECTIVES: To develop a model which calculates economic consequences of
treatment of cattle at high risk of developing Bovine Respiratory Disease (BRD
high-risk cattle), themost common and economically detrimental cattle disease in
US feedlots. Themodel had to be easily adaptable to clinical variations and regional
and timely changes in cost data. METHODS: A decision tree was developed in MS
Excel evaluating the consequences of initial treatment of BRD high-risk cattle with
tulathromycin, florfenicol, and tilmicosin on total costs and losses associated with
BRD and its treatments over an entire feeding period. Clinical data were derived
from 5 comparative trials considering success rate of initial treatment of BRD high-
risk cattle, occurrence and outcome of subsequent BRD outbreaks, chronic cases,
andmortalities. Themodel allows the estimation of results separately according to
outcomes of one of the 5 clinical trials. Cost parameters included cattle purchase,
treatment costs (first and re-treatments), costs of chronic and dead cows (perspec-
tive of the producer). RESULTS: Considering cost data derived from multiple
sources as of 2010, total costs over the entire feeding period associated with first
and subsequent BRD treatments were lowest with tulathromycin, regardless of the
study selected as basis for efficacy data. Total treatment costs for one cattle ranged
from $27.78 to $54.38 (tulathromycin), $52.83 to $84.06 (florfenicol), and $41.35 to
$141.13 (tilmicosin), and cost savings with tulathromycin were calculated between
$19.65 and $43.59 (vs. florfenicol) and $9.77 and $86.75 (vs. tilmicosin), depending
on the clinical trial considered as basis for efficacy data. Savings with tulathromy-
cin were attributed to fewer BRD treatments, less chronics and mortalities.
CONCLUSIONS: Themodel allows the estimation of total costs of treatment of BRD
high-risk cattle considering various clinical outcomes as reported in 5 trials, being
easily adaptable to high variability of cost and income data in livestock.
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OBJECTIVES: Chronic Obstructive Pulmonary Disease (COPD) is a rising concern in
high population areas, such as Mexico City, where the prevalence is estimated at
around 8%. The objective of this study was to examine if the recently available
treatment for COPD, indacaterol, was more cost-effective than the therapeutic
alternatives already available. METHODS: A cost-effectiveness analysis was per-
formed from an institutional perspective (Mexican Institute of Social Security,
IMSS). The comparators used were salmeterol and tiotropium, both alternatives
available within the National Formulary and recommended by the National Treat-
ment Guidelines for COPD. Effectiveness data was taken from published literature;
the effectiveness parameter usedwas Forced Expiratory Volume in 1 second (FEV1);
dosage regimens compared were indacaterol 300 g vs. tiotropium 18 g, and in-
dacaterol 150 g vs. salmeterol 50 g. Resource use data was obtained from the
institution; total direct costs of physician consults, lab and image tests, hospital-
ization and emergency room visits, and treatments were considered. The source of
the unit costs was the institution, current for 2010. All costs are expressed in local
currency (Mexican Pesos, MXP). The time horizon was less than 1 year; no discount
rate was used. The analytical tool used to build the model was a decision tree. A
probabilistic sensitivity analysis was performed through a Monte Carlo simulation
with 100,000 iterations to confirm the robustness of the model. RESULTS: The
results show a cost-effectiveness ratio of $13 MXP per mL of FEV1 increased for
indacaterol, compared to $13.7 MXP for tiotropium. Likewise, a cost-effectiveness
ratio of $12.9 MXP permL of FEV1 increased for indacaterol, compared to $14.3 MXP
for salmeterol, confirmed that indacaterol is a more cost-effective alternative
(dominant) for the treatment of COPD. CONCLUSIONS: From an institutional per-
spective inMexico, indacaterol is amore cost-effective (dominant) alternative than
either tiotropium or salmeterol for the treatment of COPD.
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OBJECTIVES: To evaluate the cost-effectiveness of fluticasone furoate vs. mome-
tasone furoate in the treatment of ocular symptoms in allergic rhinitis patients in
Mexico.METHODS: A decision-analytic model was developed to estimate the cost-
effectiveness of fluticasone furoate vs. mometasone furoate. Patients initiated on
treatment either completed initial therapy or switched to second line therapy due
to non-response. Probability of a switch and resource use was based on expert
panel and literature. Costs were based on local drug acquisition costs, local cost
estimates for outpatient and hospitalization. Effectiveness was defined as the net
improvement in Total Ocular Symptom Score (TOSS) at 12 weeks from Keith PK.
2009 study. The analysis was carried out from the perspective of the Mexican
health care system and all costs are reported in 2010 US dollars. RESULTS: The
corresponding health effects were 0.47 net improvement TOSS for fluticaone fu-
roate and 0.31 for mometasone furoate regimen. The mean total cost of the fluti-
caone furoate regimenwas $ 627 compared with $ 827 for the furoatemometasone
regimen. Treatment with fluticasone furoate compared to treatment with mome-
tasone furoate was less costly and resulted in a greater net improvement of TOSS.
Probabilistic sensitivity analyses demonstrated that the cost savings observed
were maintained over a wide range of alternative values for costs and resource
utilization. CONCLUSIONS: Cost-effectiveness analysis indicated the dominance
of fluticasone furoate over mometasone furoate because of both lower costs and
greater efficacy. Cost savings with fluticasone furoate were attributable to lower
drug acquisition costs. In addition, a net improvement in ocular symptomsmay be
expected in allergic rhinitis patients.
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OBJECTIVES: In Central American countries, the economic burden of tobacco has
not been assessed. In Costa Rica, a study demonstrated that tobacco-related dis-
eases represent high costs for the health system. The aim of this study was to
assess the cost-effectiveness of varenicline compared to other existing strategies
for smoking cessation within a 20-year time horizon in an adult population cohort
from Central American and the Caribbean countries using the healthcare payer’s
perspective.METHODS: The Benefits of Smoking Cessation on Outcomes (BENESCO)
simulationmodelwas used for an adult cohort in Costa Rica, Panama, Nicaragua, El
Salvador and Dominican Republic (n  19,429,581). Smoking cessation therapies
compared were varenicline (0.5–2 mg/day) versus bupropion (300 mg/day); NRT
(5-10 mg/day) and unaided cessation. Effectiveness measures were: Life-Year
gained (LYG) and quality-adjusted life-year gained (QALY’s). Resource use and
costs data were obtained from country’s Ministry of Health and/or Social Security
Institutions (2008-2009). The model used a 3% discount rate for costs (expressed in
2009 US dollars) and health outcomes. Probabilistic sensitivity analyses (PSA) were
conducted and acceptability curves were constructed. RESULTS: Varenicline re-
duced smoking-related morbidity, mortality and healthcare costs. Mortality in the
varenicline arm was reduced by 5,738, 7,425 and 14,007 deaths compared with
bupropion, NRT and unaided cessation. The net average cost per additional quitter
showed that varenicline was cost-saving against competing alternatives. The cost
per additional quitter on varenicline was US$-269 compared with bupropion and
US$2,624 compared with unaided cessation. Cost-effectiveness analyses showed
that varenicline was the dominant strategy. At a willingness-to-pay of US$10,000/
QALY, the probability that varenicline is cost-effective met 100%. PSA results sup-
port the robustness of the findings.CONCLUSIONS: Smoking cessation therapywith
varenicline is cost-saving for Central American countries. These results could help to
reduce the tobacco related disease burden and align cost-containment policies.
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OBJECTIVES: The recently made coverage decisions by UK’s NICE, Scotland’s SMC
and the allocation of $1.1Billion for comparative effectiveness research by the
United States, are strong indicators of trends in pricing and reimbursement that
are likely to be observed in the future. To gain an additional insight into these
trends,we analyzed the cost effectiveness studies for the top twenty highest selling
drugs ($80-95B worldwide sales). METHODS: The Top 20 drugs were selected
based on their worldwide sales. For this analysis, we segmented these drugs into
categories as primary care, specialty, small molecules, biologics, therapy areas and
availability of generic alternatives. We analyzed the cost effectiveness studies that
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were published in peer-reviewed journals. Search was conducted using generic
names of the drugs and the phrase “cost effectiveness” in abstract of the published
study. RESULTS: During 2003-2008, the number of published studies on “cost ef-
fectiveness” have increased by more than 30%. There is a large variability in CERs
for same drugs for different indications, in some cases also varying by biomarkers.
Primary care drugs had lower and less variable CERs than specialty drugs. Varia-
tions also exist in methodology used by different groups in modeling cost effec-
tiveness, especially for time horizon and comparator. Majority of primary care
drugs were modeled for a time horizon of 35-40 years or lifetime to demonstrate
cost effectiveness. CONCLUSIONS: This analysis shows the range, variability and
methods used for calculation of ICER values for these high budget impact drugs and
provides lessons for executives and policy makers.
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OBJECTIVES: Despite availability of current treatments, patients with chronic ob-
structive pulmonary disease (COPD), associated with chronic bronchitis, often ex-
perience frequent (life-threatening and costly) exacerbations in UK clinical prac-
tice. The aim of this analysis was to estimate the long-term costs and health
outcomes associated with the use of roflumilast in the maintenance treatment of
severe COPD in the UK setting. METHODS: A Markov model was constructed to
simulate the decline of patients through stages of COPD (as defined by the GOLD
guidelines) and death. Transition probabilities were derived from published epide-
miological sources. Community- andhospital-treated exacerbationsweremodeled
as events within each health-state. Analysis was conducted for roflumilast in dif-
ferent positions within the care pathway: replacing LABA/ICS as an add-on to LA-
MA; replacing LAMA as an add-on to LABA/ICS, and; add-on to triple therapy
(LAMALABA/ICS) vs. placebo. Relative rate ratios of exacerbations for therapeutic
regimens were derived from an independently-conducted mixed treatment com-
parison. Direct costs, health state utilities and exacerbation disutilities were
sourced fromUK costs and the published literature. Analyseswere conducted from
the UKNHS perspective, based on a 30-year time horizon, with costs and outcomes
discounted at 3% p.a. One-way and probabilistic sensitivity analyses were
conducted. RESULTS: At monthly cost of £38.23, replacement of LABA/ICS with
roflumilast was shown to be a dominant strategy, projected to improve quality-
adjusted life expectancy by 0.104 QALYs, and reduce total costs by £400. Replace-
ment of LAMAwith roflumilast yielded an ICER of £6,854/QALY; adding roflumilast
onto triple therapy yielded an ICER of £24,603/QALY. Results were sensitive to the
cost of hospital-treated exacerbations, relative rates of exacerbation and drug
costs. CONCLUSIONS: Roflumilastmay represent a cost-effective treatment option
in the UK, when used as either an add-on to, or replacement for existing agents, in
the management of severe COPD patients.
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OBJECTIVES: In Panama, between 13.5-16.5% of all deaths are associated to tobacco
consumption. The Ministry of Health (MoH) determined that tobacco use is asso-
ciated to seven of the leading causes of death in the country. The aim of this study
was to estimate the incremental cost–utility ratios for varenicline compared to
bupropion, nicotine replacement therapy (NRT) and unaided cessation for quitting
smoking using a time-horizon of 20 years from an institutional perspective.
METHODS: The Benefits of Smoking Cessation on Outcomes(BENESCO) simulation
model was used for an adult cohort of subjects (n2,249,676). BENESCO model
contains projected outcomes for cardiovascular diseases, chronic obstructive pul-
monary disease, lung cancer and stroke. The smoking cessation therapies evalu-
ated were: varenicline (0.5–2 mg/day) versus bupropion (300 mg/day), NRT (5-10
mg/day) and unaided cessation. Effectiveness and utility measures were collected
frompublished literature. Unit costs and resource use used datawas gathered from
the Panama’s MoH(2009). Costs (expressed in 2009US$) and health outcomes were
discounted at 3%. Probabilistic sensitivity analyses (PSA) were conducted.
RESULTS: Smoking cessation efficacy rates were: 22.5%; 15.7%; NRT 13.7% and 5.9%
for varenicline, bupropion, NRT andunaided cessation, respectively. After 20 years,
varenicline exhibited the highest number of QALYs gained (2,144,323) against bu-
propion (1,717 QALYs); NRT (2,222 QALYs) and unaided cessation (4,191
QALYs). QALYs differences showed to be meaningful in the healthcare system.
Costs showed varenicline is the least expensive alternative with US$311,795,928
less than NRT and US$240,956,600 less than bupropion. Varenicline dominated all
smoking cessation strategies. PSA support previous findings. Acceptability curves
showed that varenicline would be cost-effective within 3 GDP per capita
threshold. CONCLUSIONS: Results suggest that varenicline would be the cost-sav-
ing treatment. In Panama, the government is responsible by law to develop smok-
ing cessation programs, thus varenicline could be helpful to enhance cost-contain-
ment policies and improve Panama health-outcomes.
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OBJECTIVES: Chronic Obstructive Pulmonary Disease (COPD) has a huge impact on
the quality of life (QOL) of patients, diminishing significantly their ability to work
and their social activity. The objective of this study was to examine if the recently
available treatment for COPD, indacaterol, improved the QOLmore cost-effectively
than the therapeutic alternatives already available.METHODS: A cost-utility anal-
ysis was performed from an institutional perspective (Mexican Institute of Social
Security, IMSS). The comparators used were salmeterol and tiotropium, both alter-
natives availablewithin theNational Formulary and recommended by theNational
Treatment Guidelines for COPD; dosage regimens compared were indacaterol 300
g vs. tiotropium 18 g, and indacaterol 150 g vs. salmeterol 50 g. QOL data was
taken from published literature; the parameter used was health-related (HR) QOL
score using St. George’s Respiratory Questionnaire (SGRQ). Resource use data was
obtained from the institution; total direct costs of physician consults, lab and im-
age tests, hospitalization and emergency room visits, and treatments were consid-
ered. The source of the unit costs was the institution, current for 2010. All costs are
expressed in local currency (Mexican Pesos, MXP). The time horizon was less than
1 year; no discount rate was used. The analytical tool used to build the model was
a decision tree. A probabilistic sensitivity analysis was performed through aMonte
Carlo simulation with 100,000 iterations to confirm the robustness of the model.
RESULTS: The results show a cost-utility ratio of $302 MXP for indacaterol, com-
pared to $317 MXP for tiotropium. Likewise, a cost-utility ratio of $298 MXP for
indacaterol was obtained, compared to $321MXP for salmeterol, corroborating that
indacaterol is a more cost-effective alternative (dominant) for the treatment of
COPD. CONCLUSIONS: From an institutional perspective in Mexico, indacaterol
improves QOL more cost-effectively (dominant) than either tiotropium or salmet-
erol for the treatment of COPD.
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OBJECTIVES: Chronic obstructive pulmonary disease (COPD) is a degenerative con-
dition with symptoms, disability and impaired quality of life that according to
PLATINO study has 15% of prevalence in the population over 40 years-old in Brazil
with airflow obstruction who previously diagnosed with chronic bronchitis or em-
physema. This study was designed to raise the resource use and economic impact
of the exacerbation from COPD under the private healthcare system and the im-
portance of maintenance treatment avoiding exacerbation.METHODS: Amodified
Delphi panel was conducted with specialist in COPD management to capture the
clinical practice and use of resources to non severe and severe exacerbation treat-
ment. Exacerbation reduction from maintenance treatment with tiotropium was
taken from literature. Only direct medical costs were taken. For physician fees,
procedure reimbursement, inpatient costs and drug costs were gathered frompub-
lic lists (CBHPM 5th, Kairos, PHROASA) that are the base for negotiations between
providers and payers. The Brazilian guideline for economic evaluation was fol-
lowed to guarantee the methodological robustness (Vianna, 2008). Discounts were
not applied for the time horizon of 1 year. RESULTS: For each non severe exacer-
bations the total cost was R$ 413 (physician fees for emergency, ambulatory care
and consults in the hospital was R$ 180, R$ 210 for drugs and R$ 23 for oxygen
therapy) and for severe cases total cost was R$ 5,221 per patient (average LOS of 11
and cost of R$ 2,228, physician fees for consults R$ 581, R$ 483 for exams and R$
2583 for drugs and R$ 228 for oxygen therapy). Considering the incorporation of
tiotropium in the maintenance phase, a reduction of up to 25% in the average
exacerbation costs compared with the usual care of R$ 1,831. CONCLUSIONS:
Tiotropium showed potential to reduce the economical burden of COPD due to
exacerbation’s reduction and delay.
Respiratory-Related Disorders – Patient-Reported Outcomes & Preference-Based
Studies
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OBJECTIVES:This study examines the influence ofmedication-taking behaviors on
hospitalization and spending among Medicare beneficiaries with chronic obstruc-
tive pulmonary disease (COPD).METHODS: Our cohort was a random 5% national
sample of Medicare beneficiaries with COPD enrolled in stand-alone Medicare Part
D plans (PDPs) in 2006 and 2007 who used COPD maintenance medications
(n43,666). We conducted a retrospective cross-sectional analysis of the associa-
tion of COPD maintenance medication discontinuation (1/0) and adherence (Med-
ication Possession Ratio measured as low [MPR0.20], moderate [MPR 0.3-0.7] or
high [MPR0.80] on all-cause hospitalization and total, Medicare Part A, B, and D
spending. COPD diagnosis was assessed using ICD-9-CM codes (491.xx, 492.xx,
496.xx) in inpatient and outpatient administrative claims from January 1, 2006 to
June 30, 2006 (baseline). We examined outcomes for 18 months from July 1, 2006-
December 31, 2007. Maintenance medications recommended for the management
of COPD included inhaled corticosteroids (alone or in combinationwith long-acting
2–agonists), anticholinergics, and methylxanthines. Logistic regression analysis
was used to estimate any hospitalization and ordinary least squares regression to
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